Introduction
Tamoxifen, a selective estrogen receptor (ER) modulator, has proven to be effective as a treatment for advanced breast cancer, as an adjuvant therapy and as a preventative therapy in women with a high risk of breast cancer (reviewed in Dorssers et al., 2001) . However, up to 40% of cancer patients receiving adjuvant tamoxifen therapy acquire resistance to tamoxifen whereas B50% of ER-positive tumours are intrinsically resistant to tamoxifen (reviewed in Ring and Dowsett, 2004) . This has led to a number of studies to determine the cause(s) of tamoxifen resistance. Using a viral insertion mutagenesis approach, the BCAR1 (breast cancer antiestrogen resistance 1) genomic locus was identified as conferring resistance to tamoxifen (Dorssers et al., 1993) and was later shown to be the human homolog of the p130Cas rat gene product . More recently, p130Cas/BCAR1 expression has been shown to correlate with poor prognosis in ER-positive breast cancers and overexpression of p130Cas/BCAR1 promotes proliferation of estrogen-sensitive cells in the presence of antiestrogens .
p130Cas/BCAR1 is a docking protein, encompassing multiple protein-protein interaction domains within its structure (reviewed in O'Neill et al., 2000) and many p130Cas/BCAR1 interactions with downstream signalling partners are regulated by phosphorylation (Honda et al., 1998; Klemke et al., 1998; Cho and Klemke, 2000; Huang et al., 2002; Shin et al., 2004; Brabek et al., 2005) . Most of the well-characterized functions of p130Cas/ BCAR1 are related to its role in integrin-based adhesion signalling, including roles in cell migration and invasion (Cary et al., 1998; Klemke et al., 1998; Cheresh et al., 1999; Cho and Klemke, 2000; Brabek et al., 2004) , transformation (Sakai et al., 1994; Auvinen et al., 1995; Honda et al., 1998; Brabek et al., 2004) and survival signalling (Almeida et al., 2000; Cho and Klemke, 2000) . Importantly, altered regulation of integrin-based adhesion signalling can promote both survival and migration of cancer cells and p130Cas/BCAR1 has been shown to play an important role in the coordination of these processes (Chodniewicz and Klemke, 2004) . Hence, the identification of p130Cas/BCAR1 as promoting resistance to tamoxifen provides an important clue that adhesion-mediated signalling may be key in cellular response to tamoxifen.
One earlier study provides supporting evidence for a putative link between tamoxifen and adhesion-based signalling. In the study, the authors employed growth conditions that result in the formation of multicellular foci of ER-positive MCF-7 breast cancer cells and this was associated with dephosphorylation of the adhesionassociated molecule focal adhesion kinase (FAK) (Bartholomew et al., 1998) . Tamoxifen inhibited FAK dephosphorylation and concomitantly, inhibited the formation of the multicellular foci. These observations support the notion that adhesion-mediated signalling pathways may be alternately regulated in tamoxifentreated cells.
Src tyrosine kinase phosphorylates p130Cas/BCAR1 in an integrin-dependent fashion (Hamasaki et al., 1996; Vuori et al., 1996; Schlaepfer et al., 1997; Klinghoffer et al., 1999) and is thought to be the primary tyrosine kinase responsible for Cas phosphorylation (Ruest et al., 2001) . Reciprocally, p130Cas/BCAR1 can also enhance Src kinase activity (Riggins et al., 2003; Brabek et al., 2004) . Furthermore, Src tyrosine phosphorylation of the p130Cas/BCAR1 substrate domain is enhanced by the docking of both p130Cas/BCAR1 and Src to FAK (Ruest et al., 2001) . Hence there is an interdependent interaction of p130Cas/BCAR1, Src and FAK in integrin adhesion regulated by protein phosphorylation and the interaction of these three molecules can promote cell migration and survival (reviewed in Chodniewicz and Klemke, 2004) .
To study the effect of tamoxifen on adhesionmediated signalling, we have employed the MCF-7 multicellular foci growth model (Bartholomew et al., 1998) . We demonstrate phosphorylation of p130Cas/ BCAR1, FAK and Src and the survival molecule Akt following continuing exposure to tamoxifen. We show that deletion of the p130Cas/BCAR1 substrate domain appears to confer sensitivity to tamoxifen and that phosphorylation of p130Cas/BCAR1 is via a Srcmediated pathway. We further investigate the significance of enhanced Src and Akt activation, and find that chemical inhibition of these molecules can reduce viability in tamoxifen-treated MCF-7 cells.
Results
Tamoxifen suppresses ER inhibition of p130Cas/BCAR1 phosphorylation MCF-7 cells were grown as previously described (Gierthy et al., 1991; Bartholomew et al., 1998) and microscopic examination of cultures confirmed multicellular foci formation in the control cells and absence of these structures in tamoxifen-treated cultures (Figure 1a ). Measurement of cell viability using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay demonstrates that the cells grown in tamoxifen have reduced viability when compared with controls at all time points tested (Figure 1b) . However, notably there is no further decrease in cell viability between day 7 and 14, suggesting a substantial viable population of MCF-7 cells remains after 14 days exposure to tamoxifen. To confirm that the tamoxifentreated cells remaining adherent to the plate are not undergoing apoptosis, we screened cell lysates for cleavage of poly-ADP ribose polymerase (PARP), a molecule that is characteristically cleaved in apoptosis (Boulares et al., 1999) and detected no PARP cleavage in these cells (data not shown). Separately, employing techniques we have used previously (O'Neill and Golemis, 2001), we assessed nuclear morphology by 4 0 , 6 0 -diamidino-2-phenylindol staining and could not detect apoptotic nuclei (300 nuclei assessed). Hence, after 14 days treatment of MCF-7 cells with tamoxifen, the remaining adherent cell population appears to be nonapoptotic and viable.
Protein extracts were prepared from adherent tamoxifen-treated cells to investigate the effect of tamoxifen on p130Cas phosphorylation -we note that total protein from tamoxifen-treated cultures was lower than control cultures and therefore extracts were adjusted accordingly. In these extracts there is an accumulation of an upper slow-migrating band of p130Cas/BCAR1-antibody reactive protein (Figure 2a ). We note that the decrease in total p130Cas/BCAR1 expression in the ethanol control lane is not replicated in repeat experiments. Increased p130Cas/BCAR1 phosphorylation is also observed in extracts from a second ER-positive cell line, BT-474, treated with tamoxifen, although to a lesser extent than that observed in the MCF-7 cells (Figure 2b ). The slow-migrating p130Cas/BCAR1-antibody reactive protein band represents phosphorylated p130Cas/BCAR1, as treatment of immunoprecipitated p130Cas/BCAR1 with lambda phosphatase results in the loss of the upper slow-migrating form of p130Cas/ BCAR1 (Figure 2c ).
Tamoxifen has a mixed agonist/antagonist action (reviewed in Clemons et al., 2002) , therefore, to test whether the antagonist activity mediates phosphorylation effects on p130Cas/BCAR1, the pure antiestrogen ICI 182,780 was used (Howell et al., 2000; Osborne and Schiff, 2005) . The results show that phosphorylated p130Cas/BCAR1 is similarly increased in cells treated with ICI 182 780 (Figure 3a) . Following tamoxifen treatment of the ER-negative breast cancer cell lines, SKBR3, MDA-MB-231 and MDA-MB-436, there was no increase in p130Cas/BCAR1 phosphorylation (Figure 3b ), demonstrating that tamoxifen-promoted phosphorylation of p130Cas/BCAR1 requires the presence of ER. As both the ER-negative MDA-MB-231 and SKBR3 cell lines have high levels of phosphorylated p130Cas/BCAR1 under basal conditions, it was possible that there may be a correlation between p130Cas/ BCAR1 phosphorylation and ER expression. Examination of the pattern of p130Cas/BCAR1 phosphorylation in 16 ER-negative breast cancer cell lines and 8 ERpositive cell lines revealed that the majority of the ER-negative cell lines (14/16) display increased phosphorylated p130Cas/BCAR1 (ratio greater than 1, Figure 3c ). Contrasting this, 50% of the ER-positive cell lines (4/8) have less phosphorylated p130Cas/BCAR1 (ratio of upper to lower band less than 1, Figure 3c ). Thus, although there is not a direct correlation between ER status and p130Cas/BCAR1 phosphorylation, there is a trend for ER-negative cell lines to exhibit enhanced p130Cas/BCAR1 phosphorylation.
To separately compare the effects of estrogen and tamoxifen on p130Cas/BCAR1 phosphorylation, cells were grown in hormone-depleted media (phenol red-free media supplemented with charcoal stripped foetal calf serum). The media was then supplemented with tamoxifen or estrogen alone or with combined estrogen plus tamoxifen. In hormone-depleted conditions, the pattern of p130Cas/BCAR1 phosphorylation is equivalent to the pattern observed following the addition of tamoxifen alone (Figure 3d ). The predominance of phosphorylated p130Cas/BCAR1 (Figure 3d ) is not observed in cells exposed to estrogen alone, and combined exposure to estrogen and tamoxifen antagonizes the effect of estrogen on p130Cas/BCAR1 phosphorylation ( Figure 3d ). Finally, p130Cas/BCAR1 phosphorylation in hormone-depleted media or in the presence of tamoxifen does not appear to be simply due to a stress response to the loss of a critical growth factor other than estrogen, as cells grown in serum-free Dulbecco's modified Eagle's medium (DMEM) do not display altered p130Cas/BCAR1 phosphorylation in either the ER-positive cell lines, MCF-7 and BT-474 or the ER-negative cell line, MDA-MB-436 (Figure 3e ). In summary, our data suggest that estrogen regulates p130Cas/BCAR1 phosphorylation via the ER and this is antagonized by tamoxifen.
p130Cas/BCAR1 substrate domain is required for cell viability in tamoxifen The substrate-binding domain of p130Cas/BCAR1 contains the majority of the Cas consensus phosphorylation sites , therefore to test the role of the p130Cas/BCAR1 substrate domain in Adhesion signalling in tamoxifen-treated cells LN Cowell et al response to tamoxifen we prepared MCF-7 cell lines expressing mutant p130Cas/BCAR1 in which the substrate domain was deleted (YFPCasDYXXP-10) and a vector control cell line. Interestingly, following exposure to tamoxifen, there is accumulation of a second more slowly migrating form of the exogenous substrate domain-deleted protein (Figure 4a, . Therefore, this suggests that there may be other residues outside the substrate domain of p130Cas that are also phosphorylated in tamoxifen-treated cells. However, the upper CasDYXXP is a minor species in the tamoxifen-treated cells, hence the predominant phosphorylation stimulated by tamoxifen appears to occur in the substrate-binding domain.
Tamoxifen response was next compared between cell lines expressing the deletion mutant (YFPCasDYXXP-10), and the vector control (YFP-3), using an MTT cell viability assay. Importantly, the YFPCasDYXXP-10 cells have significantly decreased (less than 40%) viability in tamoxifen ( Figure 4b ). Thus, expression of p130Cas/BCAR1 in which the substrate domain has been deleted appears to reduce cell viability, suggesting that this domain contributes to viability in the presence of tamoxifen. Adhesion-dependent signalling is activated in tamoxifentreated cells Given the interdependent interaction of p130Cas/ BCAR1, Src and FAK (reviewed in Ruest et al., 2001) , we next examined the phosphorylation of these three molecules over a time course of tamoxifen treatment. Predominance of phosphorylated p130Cas is first observed following 7 days treatment with tamoxifen, whereas no increases in p130Cas phosphorylation are observed in control conditions (Figure 5a ). In contrast, we observe increased FAK phosphorylation at each time point after tamoxifen addition, with a peak of phosphorylation occurring at day 7 and extending to day 14. As the phosphorylation of FAK at Y397 is positively correlated with adhesion-dependent cell survival (Frisch et al., 1996) , FAK phosphorylation in the tamoxifen-treated cultures provides evidence to suggest that adhesion-mediated survival signalling pathways are upregulated in these cells and specifically, this pathway is enhanced in MCF-7 cells after 7 days exposure to tamoxifen.
The examination of the kinetics of Src phosphorylation in the tamoxifen-treated cultures demonstrates that Src phosphorylation is inhibited after 1 h of tamoxifen exposure (Figure 5a ). Similarly, others have reported the inhibition of Src activation by antiestrogens over short times of exposure (Migliaccio et al., 2000) . Notably, Src phosphorylation is decreased at day 1 in control cultures. By day 3, both tamoxifen and control cultures exhibit increased Src phosphorylation, however Src phosphorylation is lost in control cultures but maintained in tamoxifen-treated cultures after 7 days. Src phosphorylation then continues until at least 14 days of exposure to tamoxifen. Thus the Src kinase phosphorylation kinetics are altered by tamoxifen treatment. Notably there is also increased total Src protein after 7 and 14 days of tamoxifen treatment (Figure 5a ), when compared with control cells.
Owing to the data demonstrating phosphorylation of the adhesion-associated molecules p130Cas, FAK and Src in tamoxifen, we next tested whether phosphorylation is dependent on cell adhesion. By 24 h after suspension there is a loss of phosphorylated p130Cas/ BCAR1, Src and FAK (Figure 5b ), indicating that Adhesion signalling in tamoxifen-treated cells LN Cowell et al continued tamoxifen-promoted phosphorylation of these molecules is via an adhesion-dependent pathway. Interestingly, adhesion is also required for tamoxifen effects on total Src protein levels (Figure 5b ), suggesting that adhesion might regulate the expression levels of Src.
Together this analysis has revealed that adhesiondependent signalling is activated in MCF-7 cells treated with tamoxifen.
Activation of Src promotes survival in tamoxifen-treated cells The increased levels of activated Src in tamoxifentreated cells and the role of Src in the phosphorylation of p130Cas/BCAR1 (Ruest et al., 2001) suggested that Src may mediate p130Cas/BCAR1 phosphorylation in these cells. To explicitly address this point, we inhibited Src activity with the inhibitor PP2. Src inhibition resulted in the loss of tamoxifen promoted phosphorylation of p130Cas/BCAR1 (Figure 6a ). In contrast, there is no significant change in FAK Y397 phosphorylation in the presence of the Src inhibitor. We note that the Src inhibitor appeared to have no effect on p130Cas/ BCAR1 under control conditions (Figure 6a ), even after the addition of 20 mM PP2 (data not shown). Hence, Srcdependent phosphorylation of p130Cas appears to be specifically induced in tamoxifen-treated cells. As PP2
does not completely abrogate the phosphorylation of p130Cas/BCAR1, these data also suggest that Src is not the only kinase that phosphorylates p130Cas/BCAR1 in the MCF-7 cells.
To address the role of activated Src in response to tamoxifen, we next determined the viability of tamoxifen-treated MCF-7 cells following Src inhibition with PP2. Combined treatment with tamoxifen and PP2 resulted in a small but significant loss of cell viability, when compared with cells treated with tamoxifen alone (Figure 6b ). The effect of PP2 on cell viability is specific to cells treated with tamoxifen, as PP2 alone had no effect on the viability of MCF-7 cells (data not shown). Hence, Src activation appears to be required both to stimulate p130Cas/BCAR1 phosphorylation and enhance viability in tamoxifen.
Cells grown in tamoxifen switch on a survival signalling pathway, but not migration Previous studies of cell migration have indicated that phosphorylated p130Cas/BCAR1 localizes to ruffling cell membranes during migration (Klemke et al., 1998; Fonseca et al., 2004) and in contrast is predominantly found at focal adhesions in stationary cells (Fonseca et al., 2004) . We find that p130Cas/BCAR1 is enriched at focal adhesions in tamoxifen-treated cells (Figure 7a ), in apparent correlation with the expected localization of p130Cas/BCAR1 in stationary cells. To further test the idea that p130Cas/BCAR1 phosphorylation is related to FAK activation in tamoxifen-treated cells, cells were stained with antibodies to FAK phosphorylated at Y397 (Figure 7a) . Strikingly, the Y397-positive adhesions appear to be longer in tamoxifen-treated cells when compared to untreated controls, and to colocalize completely with p130Cas/BCAR1. We next tested whether the enrichment of p130Cas/BCAR1 at focal adhesions required Src activity by co-treating cells with tamoxifen and PP2 and determining p130Cas/BCAR1 subcellular localization. The results show that Src inhibition with PP2 appears to have no effect on p130Cas/BCAR1 localization at focal adhesions in tamoxifen-treated cells (Figure 7b ). This agrees with other studies demonstrating that Src activity is not required for p130Cas/BCAR1 localization to focal adhesions (Brabek et al., 2005) . The large focal adhesions suggests that the cells are non-motile, hence the migration of tamoxifen-treated MCF-7 cells was next assayed. In both a transwell assay of migration ( Figure 7c ) and a scratch wound assay (data not shown), no changes in migration were observed between tamoxifen and control cultures.
As earlier reports have suggested that p130Cas/ BCAR1 plays a role in both migration (Cary et al., 1998) and survival (Cho and Klemke, 2000) , we next determined whether adhesion-dependent survival signalling pathways may be switched on in tamoxifen-treated cells. A survival mediator downstream of integrin adhesion is the serine kinase Akt (Khwaja et al., 1997) . Immunoblots of protein extracts from cells treated with tamoxifen were therefore probed with antibodies to the activated form of Akt, pS473, and Figure 8a) . Akt activation appears to be Src-mediated as activation is lost in cells treated with the Src inhibitor PP2 (Figure 8b ). To address whether Akt activation can confer viaibility in tamoxifen, cells were treated with wortmannin to inhibit the upstream activator of Akt, phosphatyidylinositol 3-kinase. We note that wortmannin significantly reduces the viability of control MCF-7 cells, hence data shown are corrected for wortmannin effects (see Materials and methods). Our data show that the addition of wortmannin produces a small but statistically significant change in viability of MCF-7 cells grown in the presence of tamoxifen (Figure 8c ).
Discussion
The isolation of the adhesion-associated molecule p130Cas/BCAR1 from a screen for genes associated with antiestrogen resistance (Dorssers et al., 1993; Brinkman et al., 2000) , suggested that tamoxifen may alter the regulation of adhesion-mediated signalling. Our data suggest that antagonized ER function stimu- It was possible that the effects we observed were due to agonist effects of tamoxifen, as earlier reports have suggested that Src kinase activation can stimulate the agonist effects of tamoxifen (Pratt et al., 2005) . However, our demonstration that ICI 182, 780 gave the same effects as tamoxifen indicates that the effects we observe are due to tamoxifen antagonist effects. There is clearly a complex relationship between the ER and c-Src; c-Src can directly phosphorylate and activate the ER (Arnold et al., 1995 (Arnold et al., 1997 Pratt et al., 2005) , whereas conversely, estrogen stimulation enhances Src activation (reviewed in Migliaccio et al., 2002) . Further, estrogen can reportedly promote the association of the ER with p130Cas and Src (Cabodi et al., 2004) . However, a common feature of all of these studies is that they examine acute stimulation of ER and the responses seen were rapid and transient (Arnold et al., 1995 (Arnold et al., , 1997 Migliaccio et al., 2002; Pratt et al., 2005) . We have examined the signalling pathways in the population of cells that are viable after 14 days of tamoxifen treatment, so it is unlikely that any of these early response mechanisms explain the results we have shown.
Currently, the mechanism of Src activation following ER antagonism is unknown, but our studies indicate both increased Src protein and activity. Significantly, in a recent study Src inhibition was shown to block the proliferation of tamoxifen-resistant cell lines (PlanasSilva et al., 2006) , therefore supporting our data that Src inhibition can promote loss of viability in the presence of tamoxifen. Together, these data suggest that the regulation of ER and Src activity might be tightly controlled. Supporting this, a recent study demonstrated defective development of the mammary gland in c-Src homozygous null mice, that is phenotypically similar to ER homozygous null mice (Kim et al., 2005) . The c-Src knockout studies highlight the importance of c-Src to efficient ER signalling; however, our data now also suggest that, conversely, ER function may also be important for regulation of Src-mediated signalling in ER-dependent tissue development.
It is intriguing that we observe varied patterns of p130Cas phosphorylation in a panel of breast cancer cell lines. Given our observation that Src activation promotes p130Cas phosphorylation, it is possible that p130Cas phosphorylation may be a reflection of Src expression levels. However, we can detect no correlation between p130Cas phosphorylation status and published expression levels for Src from 13 of the cell lines that we examined (Biscardi et al., 1998) . We further considered whether p130Cas phosphorylation might reflect the epithelial or mesenchymal status of the cell lines, but again could detect no correlation between p130Cas phosphorylation and the published differentiation states for 13 of the cell lines that we examined (Lacroix and Leclercq, 2004) . Hence, it appears likely that the basal phosphorylation status of p130Cas may be determined by multiple cellular pathways. Importantly, we have shown that the substrate domain of p130Cas/BCAR1 containing the majority of the p130Cas/BCAR1 tyrosine phosphorylation sites, appears to be required for promotion of viability in the presence of tamoxifen.
Cell migration requires both the activation of migration machinery and concomitantly the upregulation of survival mechanisms. In particular, p130Cas/BCAR1 has been implicated as a key player coordinating both these processes (reviewed in Chodniewicz and Klemke, 2004) . The enhancement of survival signalling in tamoxifen-treated MCF-7 cells, may poise the cells for successful response to additional promigratory cues. There are a number of possible mechanisms to explain the separation of adhesion-based signalling effects on migration versus survival that we observe. Phosphorylation of specific p130Cas residues has previously been shown to regulate survival versus migration (Goldberg et al., 2003) , although it is as yet unclear how such specific phosphorylation events may be regulated in the cell. Therefore, the separation of these two events may reflect specific phosphorylation events. Alternatively, additional regulatory molecules that are required for Cas-promoted cell migration may not be coexpressed.
BCAR3/AND-34 (van Agthoven et al., 1998; Cai et al., 1999 ) is a second molecule identified in the screen for Breast Cancer Anti-estrogen Resistance genes and is a known interacting partner with p130Cas/BCAR1 (Cai et al., 1999) . Previous studies have shown that p130Cas/ BCAR1 interaction with AND-34 can promote cell migration (Riggins et al., 2003) ; however, there is reported to be little BCAR/AND34 expression in MCF-7 cells (Cai et al., 2003) . Interestingly, there is also an inverse correlation between BCAR3/AND-34 and ER expression (van Agthoven et al., 1998) . It is also clear that the subcellular localization of p130Cas is strongly correlated with migration (Fonseca et al., 2004) and in this context it is interesting to note that BCAR3/ AND-34 has been proposed to be required for localization of p130Cas at ruffling membranes (Riggins et al., 2003) . Finally, it has been suggested that there may be an auto-regulatory loop between integrins-FAK-c-Src and the ER that inhibits cell migration, but in response to constitutive activation of c-Src, the effects of c-Src become dominant and promote cell migration (Sisci et al., 2004) . Possibly, therefore further sustained activation of Src in MCF-7 cells following chronic exposure to tamoxifen may similarly weigh the balance in favour of a pro-migratory phenotype. Indeed, acquired tamoxifen resistance in MCF-7 cells, stimulated by 6 months continual exposure to tamoxifen (Knowlden et al., 2003) , is reported to be accompanied by increased cell invasion and motility (Hiscox et al., 2004) .
Our results raise the question of how such altered adhesion signalling might effect tumour development in vivo. Firstly, we elected to use a longer term (14 days) exposure to tamoxifen in our studies with the aim of examining adhesion-dependent signalling processes after the initial response of cells to tamoxifen. The data presented here support our use of this model, as we show that the kinetics of p130Cas/BCAR1, FAK and Src kinase phosphorylation are significantly altered in the 14 day tamoxifen cultures. Significantly, inhibition of either Src or Akt can produce a small but significant sensitization to tamoxifen, suggesting that the activation of these molecules is providing a survival advantage to some of the cell population. Costimulation of integrinbased adhesion signalling and growth factor signalling leads to a potentiated signal (reviewed in Schwartz, 1997) , therefore these cells may be primed for enhanced response to external growth factor signals. Alternatively, altered adhesion signalling may advantage any cells that are localized in specific environmental niches, for example shear stress forces in the microvasculature require rapid stabilization of cell adhesion to the vessel wall for metastasizing cells to avoid damage (Korb et al., 2004) . Tamoxifen treatment may therefore advantage a small population of cells that are in specialized environmental niches or exposed to alternative growth factors or extracellular matrix components. It will be very interesting in the future to examine the role of the increased adhesion mediated signalling in each of these potential mechanisms that we have outlined.
Our study has suggested that an adhesion-dependent survival signalling pathway can be stimulated in tamoxifen-treated cultures. Such survival signalling may be sufficient to advantage cells to survive therapy. Following previous observations suggesting that high levels of p130Cas/BCAR1 are correlated with poor response to tamoxifen, our study suggests this may be due to the role of p130Cas in adhesion-dependent survival signalling stimulated in tamoxifen-treated cultures.
Materials and methods
Cell Culture, plasmids and generation of clonal cell lines The ER-positive MCF-7 epithelial breast cancer cells were maintained in DMEM (Invitrogen, VIC, Melbourne, Australia) supplemented with 10% foetal bovine serum (FBS) (Invitrogen, VIC, Australia). All other breast cancer cell lines were maintained in Roswell Park Memorial Institute-1640 supplemented with 10% FBS, 6 mM glutamine and 5 mg/ml insulin. For estrogen-free cell culture, MCF-7 cells were cultured in phenol red-free DMEM supplemented with 10% charcoal-stripped FBS. Protein extracts from a panel of ERpositive and ER-negative breast cancer lines were kindly provided by Gillian Lerbach and Rob Sutherland from the Cancer Research Program, Garvan Institute of Medical Research, Australia. Cell growth and conditions of extraction have been previously described (Sweeney et al., 1998) . Cell lines stably expressing YFP-tagged rat p130Cas DNA in which the substrate binding domain has been deleted (YFPCas-DYXXP) were generated by transfecting MCF-7 cells with plasmid cDNAs that have been described previously (Riggins et al., 2003) . Clonal cell lines were selected by treatment with 0.5 mg/ml G418. All transfections were carried out using Lipofectamine 2000 according to the manufacturer's protocol.
Antibodies
Monoclonal antibodies against p130Cas/BCAR1 were obtained from BD Biosciences (San Diego, CA, USA) and Cas-14 was from Neo Markers (Fremont, CA, USA). Phospho-specific anti-FAK pY397 polyclonal antibody was from Biosource (Camarillo, CA, USA) and anti-FAK(C-20) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-Src (clone GD11) and phospho-specific antiSrc pY418 were from Upstate Biotechnology (Charlottesville, VA, USA) and Biosource (Camarillo, CA, USA) respectively. Antibodies to Akt and phospho-specific anti-Akt pS473 were obtained from Cell Signalling Technology (Danvers, MA, USA). Poly-clonal anti-PARP antibodies were obtained from Merck (Melbourne, Vic, Australia). Horse radish peroxidase (HRP) labelled secondary antibodies for western blot were purchased from Amersham Pharmacia Biotech (Piscataway, NJ, USA). Fluorescein isothiocyanate-labelled phalloidin was purchased from Sigma (Sydney, NSW, Australia).
Drug treatments and suspension cultures
Stock solutions of 4-hydroxytamoxifen (Sigma, NSW, Australia), 17b-estradiol (Sigma, NSW, Australia) and ICI 182,780 (gift from Dr Alan Wakeling, AstraZeneca, Cheshire, UK) were prepared in 95% ethanol. Cells (3 Â 10 5 ) were cultured in 100 mm tissue culture plates for 24 h before drug treatment. Media was then aspirated and replaced with media containing 1 mM 4-OH tamoxifen, 10 nM 17b-estradiol or 100 nM ICI 182,780. Control cells were cultured with or without ethanol vehicle. Culture media was replaced every 3-4 days over 14 days. Src inhibition was achieved by the addition of 10 mM PP2 (Merck PTY, VIC, Australia) for 48 h to 14-day tamoxifentreated and control cultures. Inhibition of PI3-K was achieved using 1 mM Wortmannin (Cell Signalling Technology, MA, USA) dissolved in dimethyl sulfoxide. Suspension cultures were prepared by trypsinizing MCF-7 cells that had been grown for 14 days in the presence or absence of tamoxifen and replating onto Poly 2-hydroxyethyl methacrylate-(Poly-HEMA) (Sigma, NSW, Australia)-coated culture dishes in the presence or absence of 1 mM 4-OH tamoxifen.
Cell viability assays Cell viability was determined using an MTT assay as previously described (Law et al., 2000) . 1 Â 10 3 cells were plated in each well of a 96-well dish at the start of the assay. Cells were incubated for 24 h, before the addition of tamoxifen, and then incubated for up to 14 days before addition of MTT substrate. For treatment with inhibitors, after 14 days exposure to tamoxifen, media was aspirated and drugs added in fresh media, along with added tamoxifen as indicated. Viability was determined by expressing the values for the treatment wells as a percentage of matching control, untreated wells. When calculating effects of PP2 and wortmannin on cell viability, any effects of drugs alone were corrected for by expressing the percent values for drug plus tamoxifen as a percentage of drug-treated controls. Results are expressed as the average values from a minimum of 18 replicates from two independent experiments or 12 replicates from three independent experiments7the standard error of the mean. Statistical significance between means was calculated using the Student's t-test.
Immunoblotting and immunoprecipitation
Protein extracts were prepared by extraction with PTY lysis buffer (50 mM N-2-hydroxyethylpiperazine-N 0 -2-ethane sulfonic acid pH 7.5, 50 mM NaCl, 5 mM ethylenediamine tetraacetate, 1% Triton-X-100 (v/v), 50 mM NaF, 10 mM Na 2 P 2 O 7 .10H 2 O) with freshly added inhibitors (1 mM Na 3 VO 4 , 1 mM polymethyl sulfonyl fluoride, 1 mg/ml aprotinin, 1 mg/ml leupeptin), as previously described (Law et al., 1996) . For suspension cultures, cells were collected by centrifugation at 320 g for 10 min and then extracted with PTY lysis buffer. Owing to growth inhibition by tamoxifen, protein extracts from tamoxifen cells were routinely of a substantially reduced protein concentration when compared with control lysates. Protein concentration was determined using the bicinchoninic acid Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA) and protein concentrations equalized. Immunoblots were routinely probed for actin expression as a loading control. Proteins were separated overnight on 6% SDS-polyacrylamide gels, followed by transfer to Immobilon transfer membrane (0.45 mm, Millipore, Billerica, MA, USA). Following incubation with indicated primary antibodies, as per manufacturer's protocols, membranes were incubated with HRP-conjugated secondary antibodies. Blots were developed using Western Lighting Chemiluminescence Reagent (PerkinElmer, Wellesley, MA, USA) and exposed to X-ray film (FujiFilm, Tokyo, Japan). Computer-assisted densitometry and analysis of p130Cas/ BCAR1 expression was achieved using ImageJ software.
Immunoprecipitations were carried out using 1 mg of total protein lysate with 10 ml of p130Cas/BCAR1 antibody for 2 h at 41C. Immune complexes were collected by incubation with protein A (20 ml of a 50% slurry) (Sigma, NSW, Australia) overnight at 41C. Immunoprecipitates were washed extensively and immunoprecipitated proteins eluted by boiling in an equal volume of gel loading buffer for 10 min. For phosphatase treatments, immunoprecipitated proteins were incubated with l phosphatase (2000 U), as per the manufacturer's protocol (New England Biolabs, Ipswich, MA, USA) for 2 h at 301C then eluted from the protein A sepharose beads by boiling. Control reactions were carried out in the absence of l phosphatase.
Immunofluorescence analysis 5 Â 10 4 MCF-7 cells were plated onto coverslips and cultured in the presence or absence of 1 mM tamoxifen for 14 days. Cells were then fixed in 4% paraformaldehyde (PFA) and permeabilized in PBS containing 0.2% Triton-X-100 before blocking in PBS containing 1% bovine albumin (BSA) (Invitrogen, VIC, Australia). Cells were incubated with primary antibodies for 3 h, followed by extensive washing and incubation with Alexa 488-(Invitrogen, VIC, Australia) or Cy3-(Jackson Immunoresearch, West Grove, PA, USA) conjugated secondary antibodies for 1 h at room temperature. Coverslips were mounted using Vector Shield (Vector Laboratories, Burlingame, CA, USA). Fluorescent confocal imaging was performed using a Leica DMRE microscope (NSW, Australia) with a Â 63 objective and a Leica SP2 confocal scanning laser. Images were captured using the Leica confocal software package. Cells were sectioned through a single optical plane, corresponding to the position of adhesion sites on the ventral side of the cell. Comparisons between antibodies were made at the same optical plane within the cell. Epifluorescence images were captured using a Spot II-cooled CCD digital camera (Diagnostics Instruments, Sterling Heights, MI, USA) mounted on an Olympus Bx50 microscope with a Â 60 objective.
Migration assay of tamoxifen-treated cells
Boyden chamber inserts (8 mm pore size), were placed in wells containing 10% FBS in DMEM plus or minus 1 mM tamoxifen. 6 Â 10 5 cells suspended in 0.2 ml serum free DMEM (plus or minus 1 mM tamoxifen) were added to the top of each chamber then incubated at 371C with 5% CO 2 . After 48 h the chambers were washed with dH 2 O and the cells removed from the topside of the chamber with a cotton swab. Migrating cells were fixed and stained using the DIFF-Quik STAIN SET (Lab-Aids, NSW, Australia). The average number of migrating cells from sixteen representative fields ( Â 20 objective, two wells per condition) was obtained from three independent experiments.
